drugs that lost patent protection during the early to mid-1980s. Our results provide strong evidence that brand-name prices …

We examine the effect of pharmaceutical patent protection on the speed of drug launch, price, and quantity in 60 … countries from 2000-2013. The World Trade Organization required its member countries to implement a minimum level of patent … potential static losses that result from reduced competition during the patent term. We take advantage of the fact that at the …

The use of “pay-for-delay” settlements in patent litigation – in which a branded manufacturer and generic entrant … settle a Paragraph IV patent challenge and agree to forestall entry – has come under considerable scrutiny in recent years … instruments include standard measures of patent strength and a measure of settlement legality based on a split between several …

Efforts to strengthen the global patent system for pharmaceuticals continue to be controversial, and what will likely …

A patent only protects an innovator from others producing the same product, but it does not protect him from others … within-patent competition, which results from production of the same product, and betweenpatent competition, which results … effects of intellectual property regulations on within -patent competition by showing how protecting innovative returns from …

to payers and consumers of pharmaceuticals. Whether the potential savings are realized depends on the extent of generic …

We examine six molecules facing initial loss of US exclusivity (LOE, from patent expiration or challenges) between June …

Generic pharmaceuticals provide low-cost access to treatment. Despite their chemical equivalence to branded products …